CYT 004 MelQbG10

Drug Profile

CYT 004 MelQbG10

Alternative Names: CYT004-MelQbG10; Melan-A VLP vaccine - Cytos; Melanoma virus-like particle vaccine - Cytos

Latest Information Update: 31 Aug 2011

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 01 Jul 2010 Cytos Biotechnology completes a phase II trial in Malignant melanoma in Switzerland
  • 24 Feb 2009 Phase II development is ongoing in Switzerland
  • 22 Nov 2007 Interim immunogenicity, adverse event and efficacy data from three phase IIa trials in malignant melanoma released by Cytos Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top